Ajg Jansen

Ajg Jansen

Auto-generated profile, based on publicly available information

Ajg Jansen

Erasmus MC University Medical Center Rotterdam the Netherlands

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
MSMaurice Swinkels
Maurice Swinkels
MRMaaike Rijkers
Maaike Rijkers
JVJan Voorberg
Jan Voorberg
Gestur VidarssonGestur Vidarsson
Gestur Vidarsson
FLFrank W. G. Leebeek
Frank W. G. Leebeek
AJA. J. Gerard Jansen
A. J. Gerard Jansen
Immune thrombocytopenia (ITP) is an autoimmune disease defined by low platelet counts which presents with an increased bleeding risk. Several genetic risk factors (e.g., polymorphisms in immunity-related genes) predispose to ITP. Autoantibodies and cytotoxic CD8+ T cells (Tc) mediate the anti-platelet response leading to thrombocytopenia. Both effector arms enhance platelet clearance through phagocytosis by splenic macrophages or dendritic cells and by induction of apoptosis. Meanwhile, platelet production is inhibited by CD8+ Tc targeting megakaryocytes in the bone marrow. CD4+ T helper cells are important for B cell differentiation into autoantibody secreting plasma cells. Regulatory Tc are essential to secure immune tolerance, and reduced levels have been implicated in the development of ITP. Both Fcγ-receptor-dependent and -independent pathways are involved in the etiology of ITP. In this review, we present a simplified model for the pathogenesis of ITP, in which exposure of platelet surface antigens and a loss of tolerance are required for development of chronic anti-platelet responses. We also suggest that infections may comprise an important trigger for the development of auto-immunity against platelets in ITP. Post-translational modification of autoantigens has been firmly implicated in the development of autoimmune disorders like rheumatoid arthritis and type 1 diabetes. Based on these findings, we propose that post-translational modifications of platelet antigens may also contribute to the pathogenesis of ITP.

2 February 2012 in Blood
Verified
Journal Article
Open access
PDF file
AJA. J. Gerard Jansen
A. J. Gerard Jansen
EJEmma C. Josefsson
Emma C. Josefsson
VRViktoria Rumjantseva
Viktoria Rumjantseva
QLQiyong Peter Liu
Qiyong Peter Liu
HFHervé Falet
Hervé Falet
KHKarin M. Hoffmeister
Karin M. Hoffmeister
When refrigerated platelets are rewarmed, they secrete active sialidases, including the lysosomal sialidase Neu1, and express surface Neu3 that remove sialic acid from platelet von Willebrand factor receptor (VWFR), specifically the GPIbα subunit. The recovery and circulation of refrigerated platelets is greatly improved by storage in the presence of inhibitors of sialidases. Desialylated VWFR is also a target for metalloproteinases (MPs), because GPIbα and GPV are cleaved from the surface of refrigerated platelets. Receptor shedding is inhibited by the MP inhibitor GM6001 and does not occur in Adam17ΔZn/ΔZn platelets expressing inactive ADAM17. Critically, desialylation in the absence of MP-mediated receptor shedding is sufficient to cause the rapid clearance of platelets from circulation. Desialylation of platelet VWFR therefore triggers platelet clearance and primes GPIbα and GPV for MP-dependent cleavage.

14 April 2022 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
DKDavid J. Kuter
David J. Kuter
MEMerlin Efraim
Merlin Efraim
JMJiri Mayer
Jiri Mayer
MTMarek Trněný
Marek Trněný
VMVickie McDonald
Vickie McDonald
NCNichola Cooper
Nichola Cooper
Rilzabrutinib, an oral, reversible covalent inhibitor of Bruton’s tyrosine kinase, may increase platelet counts in patients with immune thrombocytopenia by means of dual mechanisms of action: decreased macrophage (Fcγ receptor)–mediated platelet destruction and reduced production of pathogenic autoantibodies. In an international, adaptive, open-label, dose-finding, phase 1–2 clinical trial, we evaluated rilzabrutinib therapy in previously treated patients with immune thrombocytopenia. We used intrapatient dose escalation of oral rilzabrutinib over a period of 24 weeks; the lowest starting dose was 200 mg once daily, with higher starting doses of 400 mg once daily, 300 mg twice daily, and 400 mg twice daily. The primary end points were safety and platelet response (defined as at least two consecutive platelet counts of ≥50×103 per cubic millimeter and an increase from baseline of ≥20×103 per cubic millimeter without the use of rescue medication). Sixty patients were enrolled. At baseline, the median platelet count was 15×103 per cubic millimeter, the median duration of disease was 6.3 years, and patients had received a median of four different immune thrombocytopenia therapies previously. All the treatment-related adverse events were of grade 1 or 2 and transient. There were no treatment-related bleeding or thrombotic events of grade 2 or higher. At a median of 167.5 days (range, 4 to 293) of treatment, 24 of 60 patients (40%) overall and 18 of the 45 patients (40%) who had started rilzabrutinib treatment at the highest dose met the primary end point of platelet response. The median time to the first platelet count of at least 50×103 per cubic millimeter was 11.5 days. Among patients with a primary platelet response, the mean percentage of weeks with a platelet count of at least 50×103 per cubic millimeter was 65%. Rilzabrutinib was active and associated with only low-level toxic effects at all dose levels. The dose of 400 mg twice daily was identified as the dose for further testing. Overall, rilzabrutinib showed a rapid and durable clinical activity that improved with length of treatment. (Funded by Sanofi; ClinicalTrials.gov number, NCT03395210; EudraCT number, 2017-004012-19.)

9 April 2003 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
AJA. J. G. Jansen
A. J. G. Jansen
MEM.‐L. Essink‐Bot
M.‐L. Essink‐Bot
EBE. A. M. Beckers
E. A. M. Beckers
WHW. C. J. Hop
W. C. J. Hop
MSM. R. Schipperus
M. R. Schipperus
DRD. J. Van Rhenen
D. J. Van Rhenen
Summary. The myelodysplastic syndromes (MDS) are clonal disorders characterized by dysplasia in at least two myeloid cell lines. Fatigue is one of the most significant symptoms. MDS patients are treated with blood transfusions to improve their health‐related quality of life (HRQoL). A cross‐sectional pilot study was performed for psychometric evaluation of three internationally established HRQoL measures in MDS patients, and for investigation of the association between the severity of chronic anaemia and HRQoL. Fifty consecutive MDS patients completed the Short Form 36, the Multidimensional Fatigue Inventory and the EuroQoL‐5D Visual Analogue Scale. Hb level was measured during the same visit. Psychometric analysis focused on feasibility, construct validity and reliability. The questionnaires showed a high feasibility, reliability and validity. MDS patients had worse HRQoL scores than the age‐ and sex‐matched general population. We found a positive correlation between haemoglobin (Hb) level and HRQoL. This study provides insights into the suitability of established HRQoL measures for the evaluation of interventions in MDS patients. Hb value and HRQoL are complementary variables for evaluation of the severity of chronic anaemia in patients with MDS.

18 May 2020 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
GBGienke Bomhof
Gienke Bomhof
PMPim G. N. J. Mutsaers
Pim G. N. J. Mutsaers
FLFrank W. G. Leebeek
Frank W. G. Leebeek
PBPeter A. W. Te Boekhorst
Peter A. W. Te Boekhorst
JHJohannes Hofland
Johannes Hofland
AJA. J. Gerard Jansen
A. J. Gerard Jansen
Thrombocytopenia is a risk factor for increased morbidity and mortality in patients with the new severe acute respiratory syndrome corona virus, SARS‐CoV‐2 infection (COVID‐19 infection).1 Thrombocytopenia in COVID‐19 patients may be caused by disseminated intravascular coagulation (DIC), sepsis or drug‐induced. Recently a single case report suggested immune thrombocytopenia (ITP) may be associated with COVID‐19 infection.2 ITP is a rare autoimmune disease characterized by a platelet count < 100x109/L, leading to an increased bleeding risk.3 Several risk factors have been described for ITP including environmental (e.g. infection, malignancy and drugs) and genetic predisposition.4 We report here the first case series of three patients with ITP associated with COVID‐19 infection.

10 January 2014 in BJOG: An International Journal of Obstetrics & Gynaecology
Verified
Journal Article
Open access
PDF file
BPBw Prick
Bw Prick
AJAjg Jansen
Ajg Jansen
ESEap Steegers
Eap Steegers
WHWcj Hop
Wcj Hop
MEMl Essink‐Bot
Ml Essink‐Bot
JDJohannes Duvekot
Johannes Duvekot
Objective: To assess the effect of red blood cell (RBC) transfusion on quality of life in acutely anaemic women after postpartum haemorrhage.Design: Randomised non‐inferiority trial.Setting: Thirty‐seven Dutch university and general hospitals.Population: Women with acute anaemia (haemoglobin 4.8–7.9 g/dl [3.0–4.9 mmol/l] 12–24 hours postpartum) without severe anaemic symptoms or severe comorbidities.Methods: Women were allocated to RBC transfusion or non‐intervention.Main outcome measures: Primary outcome was physical fatigue 3 days postpartum (Multidimensional Fatigue Inventory, scale 4–20; 20 represents maximal fatigue). Non‐inferiority was demonstrated if the physical fatigue difference between study arms was maximal 1.3. Secondary outcomes were health‐related quality of life and physical complications. Health‐related quality of life questionnaires were completed at five time‐points until 6 weeks postpartum.Results: In all, 521 women were randomised to non‐intervention (n = 262) or RBC transfusion (n = 259). Mean physical fatigue score at day 3 postpartum, adjusted for baseline and mode of delivery, was 0.8 lower in the RBC transfusion arm (95% confidence interval: 0.1–1.5, P = 0.02) and at 1 week postpartum was 1.06 lower (95% confidence interval: 0.3–1.8, P = 0.01). A median of two RBC units was transfused in the RBC transfusion arm. In the non‐intervention arm, 33 women received RBC transfusion, mainly because of anaemic symptoms. Physical complications were comparable.Conclusions: Statistically, non‐inferiority could not be demonstrated as the confidence interval crossed the non‐inferiority boundary. Nevertheless, with only a small difference in physical fatigue and no differences in secondary outcomes, implementation of restrictive management seems clinically justified.